Frontlight ResearchEarly access
Taking people in NetherlandsPhase 2
Tests chemotherapy with or without darolutamide in men with advanced prostate cancer
Compares two chemotherapy drugs, with or without darolutamide, in men with prostate cancer.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- 's-Gravenhage, 'S-Hertogenbosch, Almelo, Amsterdam, Apeldoorn, Deventer, Dordrecht, Drachten, Geleen, Goes, Leeuwarden, Nijmegen, Roosendaal, Rotterdam, Schiedam, Utrecht, and Zwolle, NetherlandsSee the 18 sites
- Registry title
- DAROTAXEL
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 245 people, planned
- Started
- 28 Oct 2024
- Expected to end
- 29 Mar 2030
- Type of study
- Interventional
- Record updated
- 10 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and keeps growing despite hormone-lowering treatment. They need chemotherapy with docetaxel or cabazitaxel.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic castration-resistant prostate cancer that is getting worse (progressive), with an indication for docetaxel or cabazitaxel. Progression means growth on scans or rising PSA. PSA of 2 ng/mL or more is needed at study entry.
- Earlier treatment
- The cancer must have grown during at least one earlier hormone-blocking drug (abiraterone, apalutamide, darolutamide or enzalutamide). Docetaxel given earlier together with that drug is allowed.
- Biomarker or test result
- Blood testosterone of 1.7 nmol/L or lower. PSA of 2 ng/mL or more.
Main reasons for not taking part
- Cannot or will not take pills
- Allergy to taxane drugs
- Serious or unstable illness, for example HIV, hepatitis, organ transplant, kidney failure, severe liver disease, heart or lung disease
- Nerve damage in hands or feet with symptoms, grade 2 or higher
- Repeat treatment with docetaxel (docetaxel-rechallenge)
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥ 18 years
- A confirmed diagnosis of progressive mCRPC (progression according to Prostate cancer Working Group (PCWG) 3 criteria), with an indication for docetaxel or cabazitaxel. Progression defined as ≥ 1 of the following 3 criteria: a. Radiographic disease progression in soft tissue per RECIST v1.1 b. Radiographic disease progression in bone defined by the appearance of ≥ 2 new bone lesions on bone scan. c. PSA progression defined as ≥ 2 sequential rises in PSA obtained ≥ 1 week apart with a minimal starting value of ≥ 1 ng/mL. A PSA value ≥ 2 ng/mL is required at study entry
- Patients should have had disease progression previously on at least one ARSi (abiraterone, apalutamide, darolutamide or enzalutamide). ARSi administration is allowed both in the mCNPC and in the mCRPC setting. Coadministration of docetaxel in mCNPC (triplet-therapy) is allowed
- WHO performance ≤ 2 (see appendix A)
- Able and willing to sign the Informed Consent Form prior to screening evaluations
- Adequate haematological, renal and liver function and chemistry, defined as: a. Hemoglobin ≥ 6.0 mmol/L b. Platelets ≥ 100 x 109/L c. ALT/AST ≤ 3x ULN and ≤ 5x ULN in case of liver metastases d. Creatinine clearance ≥ 50 ml/min e. Serum testosterone ≤ 1.7 nmol/L
Who cannot take part
- Impossibility or unwillingness to take oral drugs
- Hypersensitivity to taxanes
- Known serious illness or medical unstable conditions that could interfere with this study requiring treatment (e.g. HIV, hepatitis, Varicella zoster or herpes zoster, organ transplants, kidney failure, serious liver disease (e.g. severe cirrhosis), cardiac and respiratory diseases)
- Symptomatic peripheral neuropathy CTCAE grade ≥2
- Docetaxel-rechallenge
Where in Netherlands
- Haga Hospital's-Gravenhage, NetherlandsTaking people
- Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, NetherlandsTaking people
- Ziekenhuisgroep Twente StichtingAlmelo, NetherlandsTaking people
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Gelre HospitalsApeldoorn, NetherlandsTaking people
- Deventer ZiekenhuisDeventer, NetherlandsTaking people
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
- Ziekenhuis Nij SmellingheDrachten, NetherlandsTaking people
- Zuyderland Medisch Centrum StichtingGeleen, NetherlandsTaking people
- Admiraal De Ruyter Ziekenhuis B.V.Goes, NetherlandsTaking people
- Frisius MCLeeuwarden, NetherlandsTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsTaking people
- Bravis ZiekenhuisRoosendaal, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
- Franciscus Gasthuis en VlietlandSchiedam, NetherlandsTaking people
- St Antonius ZiekenhuisUtrecht, NetherlandsTaking people
- Isala Klinieken StichtingZwolle, NetherlandsTaking people
About the trial
What the trial wants to find out
To compare progression free survival (PFS) between treatment with docetaxel or cabazitaxel and darolutamide versus treatment with docetaxel or cabazitaxel in mCRPC patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.
- Plain-language title
- Tests chemotherapy with or without darolutamide in men with advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 10 March 2026